Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cytotoxic T Lymphocytes-Medical College of Wisconsin-Adenovirus infection-Cytomegalovirus infection-Epstein-Barr virus infection
- Development stage
- Unknown
- Lead developer
- Medical College of Wisconsin
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Multi-virus Cytotoxic T Lymphocytes (CTLs) is an investigational adoptive cellular immunotherapy developed by the Medical College of Wisconsin. The product consists of donor-derived, polyclonal CD4+ and CD8+ T cells that have been expanded ex vivo to specifically recognize and target immunodominant antigens from three common opportunistic viruses: Adenovirus (Ad), Cytomegalovirus (CMV), and Epstein-Barr virus (EBV). This therapy is primarily intended for prophylaxis in pediatric recipients of T-cell depleted allogeneic hematopoietic progenitor cell transplants (HPCT). These patients are at high risk for life-threatening viral infections due to the severe immunosuppression resulting from the removal of T cells from the graft. By restoring virus-specific immunity through the infusion of these trained CTLs, the therapy aims to prevent viral reactivation and disease without inducing graft-versus-host disease (GVHD).
- Other names
- Multi-virus Cytotoxic T LymphocytesMulti-virus Cytotoxic T-cellsAd-CMV-EBV-specific CTLs
02
Targets
Ad-pMHC-I (Adenovirus peptide-major histocompatibility complex class I)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Cytotoxic T Lymphocytes-Medical College of Wisconsin-Adenovirus infection-Cytomegalovirus infection-Epstein-Barr virus infection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytotoxic T Lymphocytes-Medical College of Wisconsin-Adenovirus infection-Cytomegalovirus infection-Epstein-Barr virus infection.